HomeAI · summaries
Storia in 4 fonti
Immunotherapy combination may improve outcomes in unresectable liver cancer
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to results of the randomized phase 3 EMERALD-3 study.Using STRIDE — single-agent tremelimumab (Imjudo, AstraZeneca) and regular-interval durvalumab (Imfinzi, AstraZeneca) — with transarterial
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Regimen confers ‘meaningful’ benefit in aggressive lymphoma, may become a new standard
CHICAGO — The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the…
- ·
Immunotherapy combination may improve outcomes in unresectable liver cancer
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to…
